Board of Directors

EuroVacc Foundation is governed by the Board of Directors, which is composed of leading scientists in the fields of basic immunology and virology, molecular biology and molecular engineering, pre-clinical and clinical research. The president of the Board, Mr. Jean-Philippe Rochat is an attorney at Law and heads a law firm in Switzerland.

Frédéric Rochat - President

Frédéric Rochat is the president of the EuroVacc Foundation. Since 2008 he is partner with the law firm Kellerhals Carrard, with experience in the field of business and commercial law. Frédéric Rochat is board member and chairman of several Swiss companies and foundations.

Mariano Esteban

Mariano Esteban is professor of Spanish CSIC and former Director of the National Centre of Biotechnology (1992-2003).

Mariano Esteban is scientific professor of the Spanish Research Council (CSIC), head of the Poxvirus and Vaccines Group and former Director of the National Centre of Biotechnology (CNB) (1992-2003). He returned to Spain in 1992 after 22 years abroad, mostly in the USA, where he was professor of Biochemistry and Microbiology at Downstate Medical Center, State University of New York (SUNY), NY. 

Mariano Esteban is an internationally-recognized scientist with a long experience in molecular basis of pathogenesis by infectious agents. In particular, his group has made important contributions in understanding the lifecycle of vaccinia virus and the mechanism of action of interferons. 

Mariano Esteban used this knowledge to develop vaccinia-vectors that are candidates against prevalent human diseases caused by viruses  (HIV, hepatitis C, influenza, chikungunya, ebola, zika), parasitic (malaria and leishmania) and cancer. His group pioneered a heterologous prime/boost approach that gained acceptance as an immunization protocol against different diseases, and has made significant contributions in the biology and application of the attenuated poxvirus vectors MVA and NYVAC as vaccine candidates. Some of these vaccines have entered phase I/II clinical trials, like for HIV. During the SARS-CoV-2/COVID19 pandemic, his group developed an effective vaccine, MVA-CoV2-S donated to WHO, that fully prevented SARS-CoV-2 infection. 

Prof. Esteban is Member of prestigious Academies and societies, obtained numerous awards, currently is Ad Honorem Professor of CSIC and holds the Honorary Presidency of the Royal Academy of Pharmacy in Spain. He has published more than 400 articles in peer-review international journals, with an h-index factor of 87, directed 35 PhD thesis, generated 12 patents and 384 meeting presentations. His research is financed by national and international grants.

Jonathan Heeney

Jonathan Heeney is Professor of Comparative Pathology at the University of Cambridge where he heads The Laboratory of Viral Zoonotics.

Jonathan Heeney is Professor of Comparative Pathology at the University of Cambridge where he heads The Laboratory of Viral Zoonotics. His lab takes a One Health approach to the prevention of disease outbreaks, and his research focuses viruses that are pandemic threats that are naturally found resident in animal species. It is when viruses spill-over to humans and adapt to become human transmissible, high consequence human infections arise leading to epidemics or pandemics (notable examples include HIV, Ebola, Influenza, SARS, MERS, Lassa Fever and Monkey pox). Heeney’s early work was focused on understanding the specific types of immune responses that were necessary for a vaccine to induce robust protection from infection and/or disease. His laboratory now uses this understanding of immune correlates of vaccine protection to develop superior vaccine strategies for the best possible protective immunity. He is currently the CEO of DIOSynVax Ltd, a clinical stage vaccine Biotech that focusses on computationally designed NextGen vaccine antigens.

Giuseppe Pantaleo

Giuseppe Pantaleo is Professor of medicine and Chief of the Division of Immunology and Allergy at the Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Switzerland.

Giuseppe Pantaleo is Professor of medicine and Chief of the Division of Immunology and Allergy at the Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Switzerland. He is also the Executive Director of the Swiss Vaccine Research Institute (SVRI). Professor Pantaleo has made seminal contributions in the field of the immunopathogenesis of HIV infection. He has shown that HIV disease is active and progressive during the period of clinical latency. 

He is an internationally recognized scientist with extensive experience in the delineation of T-cell and B-cell immunity associated with different infectious diseases including HIV, HBV, tuberculosis and malaria, and has established a strong platform on the delineation of B cell maturation and generation of broadly neutralizing antibodies. He has served as the PI of multiple phase I/II clinical trials on HIV, TB and Malaria vaccines, bNabs and new drugs, and more recently COVID-19 cohort studies. He has also led multiple large research consortia funded by the European Commission and the Bill & Melinda Gates Foundation.

Jean Philippe Rochat - Honorary President

Jean-Philippe Rochat is the former president since the inception of the EuroVacc Foundation until 2017. Since 1990 he is partner with the law firm Kellerhals Carrard, with experience in the field of business and commercial law. Jean-Philippe Rochat is a member of the Board of directors and chairman of several Swiss corporations in the field of industry, finance and trading. He is member of the Board of several foundations.